Overview A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia. Phase: Phase 3 Details Lead Sponsor: Kissei Pharmaceutical Co., Ltd.